# Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

> **NCT05624268** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **COMPASS Pathways** · enrollment: 255 (estimated)

## Conditions studied

- Treatment Resistant Depression

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT05624268
- **Lead sponsor:** COMPASS Pathways
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-19
- **Primary completion:** 2025-05-28
- **Final completion:** 2026-04
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624268, "Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05624268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*